Werewolf Therapeutics (HOWL) Non Operating Interest Expenses (2023 - 2026)

Werewolf Therapeutics (HOWL) has reported Non Operating Interest Expenses for 4 consecutive years, with $475000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 63.49% year-over-year to $475000.0 in Q2 2026; TTM through Jun 2026 was $4.6 million, a 10.29% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, up 13.27% from the prior year.
• Non Operating Interest Expenses was $475000.0 for Q2 2026 at Werewolf Therapeutics, down from $1.4 million in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $1.4 million in Q4 2025 and troughed at $172000.0 in Q1 2023.
• A 4-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses soared 483.14% in 2024 and plunged 63.49% in 2026, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $1.0 million in 2023, then increased by 25.45% to $1.3 million in 2024, then advanced by 8.05% to $1.4 million in 2025, then slumped by 65.3% to $475000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $475000.0 (Q2 2026), $1.4 million (Q1 2026), and $1.4 million (Q4 2025), per Business Quant data.